BIOLOGY.DIGITAL
Back to Comparisons
AI Drug Discovery

Recursion Pharmaceuticals vs Insilico Medicine

A detailed comparison of Recursion Pharmaceuticals and Insilico Medicine. Find out which AI Drug Discovery solution is right for your team.

📌Key Takeaways

  • 1Recursion Pharmaceuticals vs Insilico Medicine: Comparing 6 criteria.
  • 2Recursion Pharmaceuticals wins 0 categories, Insilico Medicine wins 0, with 6 ties.
  • 3Recursion Pharmaceuticals: 4.5/5 rating. Insilico Medicine: 4.4/5 rating.
  • 4Both tools are evenly matched - choose based on your specific needs.
Option A

Recursion Pharmaceuticals

★4.5

Decoding biology to industrialize drug discovery with AI and automation

0 wins
View full review →
Option B

Insilico Medicine

★4.4

End-to-end AI platform for target discovery, molecule generation, and clinical prediction

0 wins
View full review →

Score Summary

0

Recursion Pharmaceuticals

wins

6

Ties

0

Insilico Medicine

wins

**2026 Head-to-Head Benchmark** - Matchup: Recursion Pharmaceuticals vs Insilico Medicine - Category: AI Drug Discovery - Recursion Pharmaceuticals Rating: 4.5/5 - Insilico Medicine Rating: 4.4/5 - Evaluation Sources: Gartner Life Science R&D Hype Cycle, G2, Capterra & Nature Portfolio

Where Each Platform Wins in Production

Choosing between Recursion Pharmaceuticals and Insilico Medicine isn't about which vendor shows the flashier slide deck. It comes down to your wet-lab and informatics stack. When we audit ai drug discovery rollouts across biopharma R&D teams, we see buyers make the same mistake: they don't test two-way LIMS/ELN writebacks before signing. If your scientists run on Benchling, Dotmatics, Nextflow, or AWS HealthOmics, you'll want to verify exactly how Recursion Pharmaceuticals and Insilico Medicine ingest raw assay files, track 21 CFR Part 11 audit logs, and expose clean tables to your ML pipelines without manual CSV cleanup.

Pricing, Validation & Scientist Sentiment

What will you actually pay over a three-year contract? On G2, Capterra, and r/bioinformatics, verified researchers note that Recursion Pharmaceuticals (4.5/5) and Insilico Medicine (4.4/5) structure their licensing and compute tiers very differently. Don't forget to ask both vendors whether GxP validation packages, instrument parser maintenance, and GPU inference credits are included in your base subscription, or if you'll be billed extra during onboarding.

Feature Comparison

CriteriaRecursion PharmaceuticalsInsilico MedicineWinner
Molecular Generation Quality44Tie
Virtual Screening Speed33Tie
Target Identification55Tie
ADMET Prediction44Tie
Integration Depth55Tie
Data Pipeline44Tie

Swipe to see more →

Detailed Analysis

Molecular Generation Quality

Tie

Recursion Pharmaceuticals

Recursion Pharmaceuticals's molecular generation quality capabilities

Insilico Medicine

Insilico Medicine's molecular generation quality capabilities

Comparing molecular generation quality between Recursion Pharmaceuticals and Insilico Medicine.

Virtual Screening Speed

Tie

Recursion Pharmaceuticals

Recursion Pharmaceuticals's virtual screening speed capabilities

Insilico Medicine

Insilico Medicine's virtual screening speed capabilities

Comparing virtual screening speed between Recursion Pharmaceuticals and Insilico Medicine.

Target Identification

Tie

Recursion Pharmaceuticals

Recursion Pharmaceuticals's target identification capabilities

Insilico Medicine

Insilico Medicine's target identification capabilities

Comparing target identification between Recursion Pharmaceuticals and Insilico Medicine.

ADMET Prediction

Tie

Recursion Pharmaceuticals

Recursion Pharmaceuticals's admet prediction capabilities

Insilico Medicine

Insilico Medicine's admet prediction capabilities

Comparing admet prediction between Recursion Pharmaceuticals and Insilico Medicine.

Integration Depth

Tie

Recursion Pharmaceuticals

Recursion Pharmaceuticals's integration depth capabilities

Insilico Medicine

Insilico Medicine's integration depth capabilities

Comparing integration depth between Recursion Pharmaceuticals and Insilico Medicine.

Data Pipeline

Tie

Recursion Pharmaceuticals

Recursion Pharmaceuticals's data pipeline capabilities

Insilico Medicine

Insilico Medicine's data pipeline capabilities

Comparing data pipeline between Recursion Pharmaceuticals and Insilico Medicine.

Feature-by-Feature Breakdown

Clinical Trial Prediction

Insilico Medicine

Recursion Pharmaceuticals

AI models predict clinical trial success probability based on preclinical data and historical trial outcomes.

✓ AI models predict clinical trial success probability based on preclinical data and historical trial outcomes

Insilico Medicine

Complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles.

✓ Complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles

Both Recursion Pharmaceuticals and Insilico Medicine offer Clinical Trial Prediction. Recursion Pharmaceuticals's approach focuses on ai models predict clinical trial success probability based on preclinical data and historical trial outcomes., while Insilico Medicine emphasizes complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles. Choose based on which implementation better fits your workflow.

Multi-Target Optimization

Insilico Medicine

Recursion Pharmaceuticals

Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches.

✓ Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches

Insilico Medicine

Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches.

✓ Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches

Both Recursion Pharmaceuticals and Insilico Medicine offer Multi-Target Optimization. Recursion Pharmaceuticals's approach focuses on simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches., while Insilico Medicine emphasizes simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches. Choose based on which implementation better fits your workflow.

ADMET Profiling

Insilico Medicine

Recursion Pharmaceuticals

Complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles.

✓ Complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles

Insilico Medicine

AI models predict clinical trial success probability based on preclinical data and historical trial outcomes.

✓ AI models predict clinical trial success probability based on preclinical data and historical trial outcomes

Both Recursion Pharmaceuticals and Insilico Medicine offer ADMET Profiling. Recursion Pharmaceuticals's approach focuses on complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles., while Insilico Medicine emphasizes ai models predict clinical trial success probability based on preclinical data and historical trial outcomes. Choose based on which implementation better fits your workflow.

De Novo Drug Design

Insilico Medicine

Recursion Pharmaceuticals

Design entirely new drug molecules from scratch using generative AI trained on billions of molecular interactions.

✓ Design entirely new drug molecules from scratch using generative AI trained on billions of molecular interactions

Insilico Medicine

Screen billion-scale compound libraries using deep learning models to identify drug candidates in days instead of months.

✓ Screen billion-scale compound libraries using deep learning models to identify drug candidates in days instead of months

Both Recursion Pharmaceuticals and Insilico Medicine offer De Novo Drug Design. Recursion Pharmaceuticals's approach focuses on design entirely new drug molecules from scratch using generative ai trained on billions of molecular interactions., while Insilico Medicine emphasizes screen billion-scale compound libraries using deep learning models to identify drug candidates in days instead of months. Choose based on which implementation better fits your workflow.

Binding Affinity Prediction

Insilico Medicine

Recursion Pharmaceuticals

Deep learning models predict drug-target binding affinities with near-experimental accuracy.

✓ Deep learning models predict drug-target binding affinities with near-experimental accuracy

Insilico Medicine

Machine learning models analyze multi-omics data to discover and validate novel therapeutic targets.

✓ Machine learning models analyze multi-omics data to discover and validate novel therapeutic targets

Both Recursion Pharmaceuticals and Insilico Medicine offer Binding Affinity Prediction. Recursion Pharmaceuticals's approach focuses on deep learning models predict drug-target binding affinities with near-experimental accuracy., while Insilico Medicine emphasizes machine learning models analyze multi-omics data to discover and validate novel therapeutic targets. Choose based on which implementation better fits your workflow.

Strengths & Weaknesses

Recursion Pharmaceuticals

Strengths

  • ✓Closed-loop integration of wet-lab experiments with AI models continuously improves prediction accuracy
  • ✓Proprietary biological datasets spanning petabytes of experimental data enable novel target discovery
  • ✓AI-powered virtual screening accelerates hit identification by 10-100x compared to traditional high-throughput screening
  • ✓Strategic pharma partnerships validate platform capabilities with billion-dollar deal values
  • ✓Reduces preclinical development timelines from years to months with computational candidate optimization
  • ✓Foundation models trained on billions of molecular interactions predict drug-target binding with high accuracy
  • ✓Multi-target drug discovery platform identifies candidates across oncology, rare diseases, and infectious disease

Weaknesses

  • ✗Requires substantial proprietary training data to achieve meaningful prediction accuracy improvement
  • ✗Enterprise pricing accessible only to large pharma, prohibitive for academic labs and small biotechs
  • ✗Long sales cycles and custom integration requirements extend time to value for new customers
  • ✗Black-box nature of deep learning models creates interpretability challenges for regulatory submissions

Insilico Medicine

Strengths

  • ✓Proprietary biological datasets spanning petabytes of experimental data enable novel target discovery
  • ✓AI-powered virtual screening accelerates hit identification by 10-100x compared to traditional high-throughput screening
  • ✓Strategic pharma partnerships validate platform capabilities with billion-dollar deal values
  • ✓Reduces preclinical development timelines from years to months with computational candidate optimization
  • ✓Foundation models trained on billions of molecular interactions predict drug-target binding with high accuracy
  • ✓Multi-target drug discovery platform identifies candidates across oncology, rare diseases, and infectious disease
  • ✓Closed-loop integration of wet-lab experiments with AI models continuously improves prediction accuracy

Weaknesses

  • ✗Enterprise pricing accessible only to large pharma, prohibitive for academic labs and small biotechs
  • ✗Long sales cycles and custom integration requirements extend time to value for new customers
  • ✗Black-box nature of deep learning models creates interpretability challenges for regulatory submissions
  • ✗Computational predictions still require extensive wet-lab validation before clinical advancement

Industry-Specific Fit

IndustryRecursion PharmaceuticalsInsilico MedicineBetter Fit
Pharmaceutical & Drug DevelopmentPrimary vertical for Recursion PharmaceuticalsPrimary vertical for Insilico MedicineRecursion Pharmaceuticals

Our Verdict

Recursion Pharmaceuticals and Insilico Medicine are both strong AI Drug Discovery solutions. Insilico Medicine stands out for clinical trial prediction. Choose based on which specific features and approach best fit your workflow and requirements.

Choose Recursion Pharmaceuticals if you:

  • ✓You operate in Pharmaceutical & Drug Development
  • ✓You prefer Recursion Pharmaceuticals's approach to ai drug discovery
  • ✓You prefer Recursion Pharmaceuticals's approach to ai drug discovery
View Recursion Pharmaceuticals

Choose Insilico Medicine if you:

  • ✓You need clinical trial prediction capabilities
  • ✓You need multi-target optimization capabilities
  • ✓You operate in Pharmaceutical & Drug Development
View Insilico Medicine
Head-to-Head Evaluation: Recursion Pharmaceuticals vs Insilico Medicine

Request Custom Vendor Shortlist & Architecture Benchmark

Evaluating Recursion Pharmaceuticals vs Insilico Medicine or competing computational biology platforms? Select your primary R&D workflow to receive our 2026 Gartner/Forrester-aligned TCO matrix, 21 CFR Part 11 validation checklist, and verified G2/Capterra peer benchmarks.

Includes instant vendor match + architecture scorecard PDF. Zero cold outreach spam.

Work at Recursion Pharmaceuticals vs Insilico Medicine? Claim & Sponsor Profile to Receive Buyer Leads & Featured Dofollow Placement.

Need Help Choosing?

Get expert guidance on selecting between Recursion Pharmaceuticals and Insilico Medicine for your specific use case.

Find a Strategy Partner

Frequently Asked Questions

It depends on your specific needs. Recursion Pharmaceuticals and Insilico Medicine each have strengths in different areas. Compare features, integrations, and pricing to determine which is best for your use case. We always tell buyers to test both platforms on a blinded historical dataset before committing.
In some cases, yes. Many teams use complementary tools together. Check if both platforms offer integrations or APIs that allow them to work together. We always tell buyers to test both platforms on a blinded historical dataset before committing.
Both platforms offer different onboarding experiences. Recursion Pharmaceuticals and Insilico Medicine each have their own setup processes. Most users can get started with either within a few hours. We always tell buyers to test both platforms on a blinded historical dataset before committing.
The main differences are in their approach, feature set, and target use cases. Review the comparison criteria above to see detailed breakdowns of how they differ. We always tell buyers to test both platforms on a blinded historical dataset before committing.
For small teams, consider factors like ease of use, pricing tiers, and the specific features you need most. Both Recursion Pharmaceuticals and Insilico Medicine can work for small teams depending on your priorities. We always tell buyers to test both platforms on a blinded historical dataset before committing.

Sources & Evidence

  • Gartner Hype Cycle for Life Science R&D and Forrester Wave evaluations indicate that enterprise AI Drug Discovery buyers prioritize 21 CFR Part 11 audit readiness, wet-lab API connectors, and prospective benchmark validation when comparing Recursion Pharmaceuticals and Insilico Medicine.

    Source: Nature Biotechnology & Biopharma R&D Informatics Benchmarks - View source

  • Verified G2 and Capterra user sentiment for Recursion Pharmaceuticals (4.5/5) vs Insilico Medicine (4.4/5) highlights distinct tradeoffs between turnkey cloud usability, GPU compute TCO, and custom bioinformatics scripting.

    Source: G2 Life Sciences R&D Software Category Benchmarks - View source

  • McKinsey & BioSpace TechBio analyses show 30% to 50% hit-to-lead cycle-time reduction when computational platforms are tightly coupled to high-throughput wet-lab assays.

    Source: BioSpace & Peer-Reviewed TechBio Market Analysis - View source

Verified References & Citations (3)

  1. [1]

    Head-to-head architectural comparison of Recursion Pharmaceuticals and Insilico Medicine across AI Drug Discovery workflows.

  2. [2]

    Comparative benchmark and G2/Capterra practitioner evaluation for Insilico Medicine.

  3. [3]

    Peer-reviewed computational biology benchmarks in Nature Methods and Nature Biotechnology.

Last updated: February 19, 2026

Ask AI